Top Markets
Coin of the day
Hillstream BioPharma, Inc. Hillstream BioPharma, Inc.

Hillstream BioPharma, Inc.

HILS
Rang in aandelen #37089
Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed... Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.
Aandeelprijs
$0.181
Laatst gesynchroniseerd: 2023-10-20
Marktkapitalisatie
$2.03M
Verandering (1 dag)
-9.45%
Verandering (1 jaar)
0.00%
Land
US
Handel Hillstream BioPharma, Inc. (HILS)

Categorie

EPS voor Hillstream BioPharma, Inc. (HILS)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Hillstream BioPharma, Inc. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Hillstream BioPharma, Inc. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten